Aptar Pharma to showcase an industry first12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.
Aptar Pharma will showcase an industry first with its PureHale device – a new portable drug delivery device designed for upper respiratory care - at CPhI Worldwide this year in Madrid.
In addition to PureHale, Aptar Pharma will also reveal:
“Through a wide range of consulting and services, Aptar Pharma innovates around delivery routes, effective drug delivery, testing and regulatory requirements with partners ranging from small-scale R&D firms to the largest international pharmaceutical companies. We look forward to launching our Support Services initiative at CPhI, and working with our customers to meet their development needs, said Guillaume Brouet, Vice President Analytical, Regulatory and Scientific Affairs at Aptar Pharma.”
Along with showcasing its range of innovative drug delivery devices that address nasal, pulmonary, eye care, injectables and dermal drug delivery routes at Aptar Pharma’s exhibit stand, the company will also be sharing various new solutions in prescription and over-the-counter treatments.
Furthermore, Aptar Pharma executives will be delivering three Pharma Insight Briefings outlining the latest trends, technology and product innovations:
“Debunking the leachable myths of gamma sterilization: A migration study of steam vs gamma”
Julie D. Suman, President of Next Breath, a division of Aptar Pharma, Tuesday 9 October, 11:50-12:20.
Julie Suman will present a migration study commissioned by Aptar Pharma to assess the impact of both steam sterilization and gamma sterilization on leachable profiles.
“Portable care for your respiratory tract: Exploring new technology platforms”
Guenter Nadler, Director Business Development, Aptar Pharma, Tuesday 9 October, 12:30-13:00
Guenter Nadler will discuss new trends in treating upper respiratory tract issues naturally, including new respiratory technology platforms that will meet new market needs.
“Building a connected devices eco-system for digital medicines”
Sai Shankar, Director Business Development, Aptar Pharma Wednesday 10 October, 13:50-14:20.
Sai Shankar will highlight the need for a digital medicine eco-system to ensure connected devices are fully optimised through patient-centric design, secure data collection and management, and cross-platform interoperability.
FDA approves first generic version of Sabril tablets
17 Jan 2019
Approval of generic vigabatrin tablets granted to Teva Pharmaceuticals USA.Read more
New software platform improves freeze drying process control
16 Jan 2019
The LyoS 2.0 control system software is fully configurable and fully validatable for regulated pharmaceutical and biotechnology applications.Read more
Preparing samples of cannabis plant for THC/CBD analysis
15 Jan 2019
Porvair Sciences has created a solid, stable and strong microplate that can withstand the applied forces in bead-beaters while maintaining a standard ANSI/SLAS footprint and key dimensions.Read more
BASF’s new active ingredients target skin conditions’ root causes
15 Jan 2019
New active ingredients coming from the research of BASF’s innovation platforms on epigenetics, microbiome and extraction.Read more
MedPharm expands to de-risk customers' development programs
14 Jan 2019
The $4-million investment will be used to expand topical dosage formulation development services and innovative performance testing on topical and transdermal pharmaceutical products.Read more
Univercells introduces breakthrough vaccine manufacturing platform
13 Jan 2019
The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.Read more
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Lilly to bag Loxo Oncology for $8 billion
8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.Read more
Catalent to double its commercial biomanufacturing capacity
7 Jan 2019
The $200-million expansion will support customers’ development programs and commercial launches.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation